These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 18284457)

  • 21. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
    Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
    Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution.
    Balduini CL; Guarnone R; Pecci A; Centenara E; Invernizzi R; Ascari E
    Haematologica; 1999 Jan; 84(1):12-6. PubMed ID: 10091387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System.
    Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R
    Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
    Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
    J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
    Sakuma T; Hayashi Y; Kanomata N; Murayama T; Matsui T; Kajimoto K; Hanioka K; Chihara K; Maeda S
    Pathol Int; 2006 Apr; 56(4):191-9. PubMed ID: 16634964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.
    Ohyashiki JH; Iwama H; Yahata N; Ando K; Hayashi S; Shay JW; Ohyashiki K
    Clin Cancer Res; 1999 May; 5(5):1155-60. PubMed ID: 10353751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome.
    Wang H; Wang XQ; Xu XP; Lin GW
    Cancer Genet Cytogenet; 2010 Jan; 196(2):159-66. PubMed ID: 20082852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.
    Germing U; Lauseker M; Hildebrandt B; Symeonidis A; Cermak J; Fenaux P; Kelaidi C; Pfeilstöcker M; Nösslinger T; Sekeres M; Maciejewski J; Haase D; Schanz J; Seymour J; Kenealy M; Weide R; Lübbert M; Platzbecker U; Valent P; Götze K; Stauder R; Blum S; Kreuzer KA; Schlenk R; Ganser A; Hofmann WK; Aul C; Krieger O; Kündgen A; Haas R; Hasford J; Giagounidis A
    Leukemia; 2012 Jun; 26(6):1286-92. PubMed ID: 22289990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Myelodysplastic syndromes].
    Garandeau C; Pautas E; Andreux M; Andreux J; Gaussem P; Siguret V
    Ann Biol Clin (Paris); 2000; 58(4):405-16. PubMed ID: 10932040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes.
    Golshayan AR; Jin T; Maciejewski J; Fu AZ; Bershadsky B; Kattan MW; Kalaycio ME; Sekeres MA
    Br J Haematol; 2007 Apr; 137(2):125-32. PubMed ID: 17391492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.
    Lauseker M; Schemenau J; Strupp C; Kündgen A; Gattermann N; Hasford J; Germing U
    Br J Haematol; 2015 Sep; 170(5):687-93. PubMed ID: 25960152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count.
    Jacobs NL; Holtan SG; Porrata LF; Markovic SN; Tefferi A; Steensma DP
    Am J Hematol; 2010 Mar; 85(3):160-3. PubMed ID: 20131304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome.
    Lee JH; Lee JH; Shin YR; Lee JS; Kim WK; Chi HS; Park CJ; Seo EJ; Lee KH
    Leukemia; 2003 Feb; 17(2):305-13. PubMed ID: 12592327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
    Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
    Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
    Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
    Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
    Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.